logo

VOR

Vor Biopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Strong Buy"
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About VOR

Vor Biopharma Inc.

A clinical stage cell therapy company to develop therapies for hematological malignancies patients

Biological Technology
12/30/2015
02/05/2021
NASDAQ Stock Exchange
159
12-31
Common stock
100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140
--
Vor Biopharma Inc., a wholly-owned subsidiary of PureTech Health LLC, was incorporated in Delaware on December 30, 2015. The company is a clinical-stage cell therapy company that combines novel patient engineering approaches and targeted therapies to provide a single company solution for patients with hematological malignancies. The company's proprietary platform leverages its expertise in hematopoietic stem cell biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. Vor is headquartered in Cambridge, Massachusetts.

Company Financials

EPS

VOR has released its 2024 Q4 earnings. EPS was reported at -0.44, versus the expected -0.31, missing expectations. The chart below visualizes how VOR has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime